Literature DB >> 7890309

An endogenous lectin, galectin-3 (epsilon BP/Mac-2), potentiates IL-1 production by human monocytes.

K C Jeng1, L G Frigeri, F T Liu.   

Abstract

Galectin-3 is a member of a growing family of beta-galactoside-binding animal lectins and previously designated as epsilon BP (IgE-binding protein) by this laboratory and as Mac-2, CBP35, L-34 and L-29 by other researchers. While possible intracellular functions have been proposed for galectin-3, existing data also suggest an extracellular modulatory role of this lectin. For example, epsilon BP/Mac-2 was found to be secreted by various cells and capable of activating mast cells, possibly through cross-linking of cell surface glycoproteins involved in cell activation. In this study, we showed that epsilon BP bound to human monocytes via its lectin function. Furthermore, we found that epsilon BP potentiated IL-1 production by monocytes in a manner that was inhibitable by the saccharide ligand of epsilon BP. The results further support a role of this lectin in potentiating activities of inflammatory cells and thereby amplifying inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7890309     DOI: 10.1016/0165-2478(94)90072-8

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  27 in total

1.  Kinetic measurements of binding of galectin 3 to a laminin substratum.

Authors:  E A Barboni; S Bawumia; R C Hughes
Journal:  Glycoconj J       Date:  1999-07       Impact factor: 2.916

Review 2.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 3.  Seeing strangers or announcing "danger": galectin-3 in two models of innate immunity.

Authors:  Sachiko Sato; Julie Nieminen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 4.  Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses.

Authors:  Gabriel A Rabinovich; Marta A Toscano; Juan M Ilarregui; Natalia Rubinstein
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 5.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

6.  Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries.

Authors:  E Jensen-Jarolim; C Neumann; G Oberhuber; R Gscheidlinger; C Neuchrist; W Reinisch; R I Zuberi; E Penner; F T Liu; G Boltz-Nitulescu
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

7.  Galectin-3 expression in response to LPS, immunomodulatory drugs and exogenously added galectin-3 in monocyte-like THP-1 cells.

Authors:  Sanja Dabelic; Ruder Novak; Sandra Supraha Goreta; Jerka Dumic
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-08-15       Impact factor: 2.416

8.  Critical role of galectin-3 in phagocytosis by macrophages.

Authors:  Hideki Sano; Daniel K Hsu; John R Apgar; Lan Yu; Bhavya B Sharma; Ichiro Kuwabara; Shozo Izui; Fu-Tong Liu
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.

Authors:  Sean R Stowell; Connie M Arthur; Padmaja Mehta; Kristen A Slanina; Ola Blixt; Hakon Leffler; David F Smith; Richard D Cummings
Journal:  J Biol Chem       Date:  2008-01-23       Impact factor: 5.157

10.  Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum.

Authors:  K P Mathews; K N Konstantinov; I Kuwabara; P N Hill; D K Hsu; B L Zuraw; F T Liu
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.